Search clinical trials for: telmisartan plus hydrochlorothiazide

Total 5426 results

Bayer

Completed

Effects of Telmisartan/Hydrochlorothiazide Treatment in Hypertensive Patients Under Real-life Setting (POTASSIUM)

Primary Hypertension

Poland
Boehringer Ingelheim

Completed

A Study of a Hypertensive Population Under Treatment With Micardis® and Micardis Plus® to Control the Early Morning BP Rise (SURGE II)

Hypertension
Boehringer Ingelheim

Completed

Telmisartan Tab Hypertension

Hypertension
Boehringer Ingelheim

Completed

Safety Evaluation of Telmisartan Plus Hydrochlorothiazide in Patients With Mild-to-Moderate Hypertension

Hypertension
Boehringer Ingelheim

Completed

3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension

Hypertension

Japan
Boehringer Ingelheim

Withdrawn

Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice

Hypertension

Japan
Boehringer Ingelheim

Completed

Telmisartan With or Without Hydrochlorothiazide in Patients With Mild-to-moderate Hypertension

Hypertension
Boehringer Ingelheim

Completed

Telmisartan Plus Hydrochlorothiazide in Subjects With Mild-to-moderate Hypertension Who Failed to Respond to Telmisartan Monotherapy

Hypertension
Boehringer Ingelheim

Completed

An Observational Study to Investigate the Efficacy, Safety, Tolerability and the Effect on Quality of Life of Telmisartan (Micardis) and Telmisartan With HCTZ (Micardis Plus) in Patients With Hypertension

Hypertension

Korea, Republic of
Boehringer Ingelheim

Completed

Post-marketing Surveillance Study With MicardisPlus® in Treatment of Morning Hypertension (Self-monitored by Patient)

Hypertension
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan / HCTZ Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan / HCTZ of Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers

Healthy
Boehringer Ingelheim
Astellas Pharma Inc

Completed

Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term Use

Hypertension

Japan
Boehringer Ingelheim

Completed

Evaluation of the Effect of Telmisartan on Blood Pressure Control of High Risk Patients

Hypertension

Romania
Boehringer Ingelheim

Completed

Influence of Food on the Bioavailability of Two Doses of Telmisartan/HCTZ Fixed-dose Combination in Japanese Healthy Male Volunteers

Healthy
IlDong Pharmaceutical Co Ltd

Completed

Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients

Essential Hypertension

Korea, Republic of
Boehringer Ingelheim

Completed

PROBE Parallel 6-week Treatment Comparing Telmisartan/Hydrochlorothiazide (HCT) (40/12.5 or 80/12.5) With Losartan/HCT (50/12.5) Using Ambulatory Blood Pressure Monitoring (ABPM)

Hypertension

United States
Bayer

Completed

Therapy of Essential Hypertension With Kinzal®/ Kinzalplus®

Hypertension

Switzerland
Tokyo University

Completed

Evaluation of Effect of Combination With Telmisartan and Hydrochlorothiazide in Hypertensives Uncontrolled on Amlodipine (ONEAST)

Essential Hypertension

Japan
Yonsei University

Completed

Randomized, Open Labeled Clinical Trial to Compare the Effectiveness of Amlodipine/Valsartan vs Hydrochlorothiazide/Telmisartan on Glucose Tolerance in Patients With Hypertension With Metabolic Syndrome

Hypertension

Korea, Republic of
Boehringer Ingelheim

Completed

Pharmaco-epidemiological Study Describing a Population of Hypertensive Patients Treated With a Fixed-dose Combination of Telmisartan and Hydrochlorothiazide

Hypertension
Boehringer Ingelheim

Completed

A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients

Hypertension

United States
Boehringer Ingelheim

Completed

SMOOTH - Blood Pressure Control in Diabetic/Obese Patients

Hypertension | Diabetes Mellitus, Type 2

Taiwan, Korea, Republic of, United States, New Zealand, Australia, Argentina, Canada, Mexico
Boehringer Ingelheim

Completed

TELSYS - TELmisartan Effectiveness in Isolated SYStolic Hypertension Versus Systolic/Diastolic Hypertension Patients Aged 55 or Older (TELSYS)

Hypertension
Boehringer Ingelheim

Completed

Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension

Hypertension

United States
Boehringer Ingelheim

Completed

A Randomized, Double-blind, Parallel-group Assessment of the Safety and Efficacy of Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg (Micardis Plus) in Comparison With Losartan 50mg Plus Hydrochlorothiazide 12.5mg in Taiwanese Patients With Mild to Moderate Hypertension

Hypertension

Taiwan
Boehringer Ingelheim

Completed

Evaluation of Efficacy and Tolerability of Micardis® / MicardisPlus® Under Usual Daily-practice Prescribing in Patients With Hypertension

Hypertension
Boehringer Ingelheim

Completed

Open-label Follow-up Trial of Fixed Dose Combination of Telmisartan + Hydrochlorothiazide in Hypertensive Patients

Hypertension

France, Switzerland, Italy, Germany, Hong Kong, Netherlands, South Africa, Spain, Denmark, Sweden, Finland, Ireland, Korea, Republic of, Malaysia, Norway, Taiwan
IlDong Pharmaceutical Co Ltd

Completed

Clinical Trial to Compare the Pharmacokinetics of TAH Tablet in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers

Healthy

Korea, Republic of
Coordinación de Investigación en Salud, Mexico

Completed

Use of Telmisartan and Captopril in Inflammation of Hemodialysis Patients

Inflammation | End-stage Renal Disease

Mexico
Boehringer Ingelheim

Completed

Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With Hypertension

Hypertension

Japan
Boehringer Ingelheim

Completed

Relative Bioavailability of Telmisartan and HCTZ in Two Experimental Formulations Compared to the Standard Formulation Telmisartan and HCTZ in Healthy Female and Male Subjects

Healthy
IlDong Pharmaceutical Co Ltd

Completed

Compare the Pharmacokinetics of TAH(80/10/12.5) Tablet in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers

Healthy

Korea, Republic of
Laboratorio Elea Phoenix S.A.
Carlos R. Rojo, MD; Facultad de Medicina, Universidad de Buenos Aires, UBA

Completed

Telmisartan for Treatment of COVID-19 Patients

COVID-19 Drug Treatment

Argentina
Boehringer Ingelheim

Completed

A Comparison of Telmisartan + Hydrochlorothiazide With Amlodipine + Hydrochlorothiazide in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension (ATHOS Study)

Hypertension

Italy, Germany, Netherlands, France, South Africa, Belgium, Denmark, Finland, Ireland, Spain
Boehringer Ingelheim

Completed

Pharmacokinetics of Different Formulations of Telmisartan, Amlodipine, and Hydrochlorothiazide (HCTZ) in Japanese Healthy Male Volunteers

Healthy

Japan
Boehringer Ingelheim

Completed

Add-on to Micamlo BP Trial

Hypertension

Japan
Yuhan Corporation

Not yet recruiting

Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension

Essential Hypertension

Korea, Republic of
University of Abuja
Imperial College London; University College Hospital, Ibadan; University of Nairobi and other collaborators

Completed

Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans (Creole)

Hypertension

Nigeria
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan/ HCTZ Fixed Dose Combination Compared With Its Monocomponents in Healthy Male Volunteers II

Healthy
Boehringer Ingelheim

Completed

Telmisartan80/HCTZ25 Versus Telmisartan80/HCTZ12.5 in Hypertension Not Responding to Telmisartan80/HCTZ12.5

Hypertension

France, Switzerland, Italy, Germany, Hong Kong, Netherlands, South Africa, Spain, Taiwan, Denmark, Sweden, Finland, Ireland, Korea, Republic of, Malaysia, Norway
Boehringer Ingelheim

Completed

Relative Oral Bioavailability of Telmisartan / Hydrochlorothiazide (HCTZ) Fixed Dose Combination (FDC) Compared With Its Monocomponents in Healthy Subjects

Healthy
Third Military Medical University

Completed

A Randomized, Double-Blind, Active Control Trial Comparing Effects of Telmisartan, Candesartan and Amlodipine, Alone or Plus Metformin, on Non-Diabetic, Obese Hypertensive Patients (HOT-ACME)

Hypertension | Obesity

China
Boehringer Ingelheim

Completed

Study to Evaluate the Effect of Micardis® / MicardisPlus® on Metabolic Parameters in Patients With Essential Hypertension and Diabetes Mellitus

Hypertension
Boehringer Ingelheim

Completed

Micardis® / MicardisPlus® Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases (PROTEKT)

Hypertension
Boehringer Ingelheim

Completed

Study to Evaluate the Effect of the Treatment With Micardis® or MicardisPlus® on Blood Pressure

Hypertension
Boehringer Ingelheim

Completed

Telmisartan Compared to Losartan + Hydrochlorothiazide in Patients With Mild-to-moderate Essential Hypertension

Hypertension
Boehringer Ingelheim

Completed

An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination

Hypertension

Japan
Novartis

Completed

Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Fixed Dose Combination in Hypertensive Patients Not Controlled by the Free Combination of an Angiotensin Receptor Blocker Plus Hydrochlorothiazide

Hypertension

Switzerland, Germany
Stendhal Americas, S.A.

Completed

Efficacy and Safety of Fimasartan Alone or Combined With HCTZ in Mexican Patients With Essential Hypertension (FIRME-1)

Hypertension, Essential

Mexico

3

Subscribe